The TSC1-TSC2 complex: A molecular switchboard controlling cell growth

Biochemical Journal

Volumn 412, Issue 2, 2008, Pages 179-190

  Huang, Jingxiang ^a   Manning, Brendan D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cell growth control; Hamartin (TSC1); Mammalian target of rapamycin complex 1 (mTORC1); Ras homologue enriched in brain (Rheb); Tuberin (TSC2); Tuberous sclerosis complex (TSC)

Indexed keywords

CELL GROWTH; ENZYME ACTIVITY; PHOSPHORYLATION; PROTEINS; SIGNAL TRANSDUCTION; TUMORS;

CELL GROWTH CONTROL; HAMARTIN (TSC1); MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1 (MTORC1); RAS HOMOLOGUE ENRICHED IN BRAIN (RHEB); TUBERIN (TSC2); TUBEROUS SCLEROSIS COMPLEX (TSC);

GENE EXPRESSION;

AMINO ACID DERIVATIVE; CYTOKINE; HAMARTIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHEB PROTEIN; S6 KINASE; SOMATOMEDIN C; TUBERIN;

CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CELL STRESS; COMPLEX FORMATION; GENE IDENTIFICATION; GROWTH REGULATION; HUMAN; NONHUMAN; OXYGEN SENSING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE; CELL GROWTH PROCESSES; GENES, TUMOR SUPPRESSOR; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; MONOMERIC GTP-BINDING PROTEINS; NEUROPEPTIDES; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 44449161481     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20080281     Document Type: Review

References (130)

1. Kandt, R. S., Haines, J. L., Smith, M., Northrup, H., Gardner, R. J., Short, M. P., Dumars, K., Roach, E. S., Steingold, S., Wall, S. et al. (1992) Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 2, 37-41
2. Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305-1315
3. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805-808
4. Carsillo, T., Astrinidis, A. and Henske, E. P. (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. U.S.A. 97, 6085-6090
5. Crino, P. B., Nathanson, K. L. and Henske, E. P. (2006) The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345-1356
6. Wienecke, R., Konig, A. and DeClue, J. E. (1995) Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270, 16409-16414
7. Xiao, G. H., Shoarinejad, F., Jin, F., Golemis, E. A. and Yeung, R. S. (1997) The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 272, 6097-6100
8. Maheshwar, M. M., Cheadle, J. P., Jones, A. C., Myring, J., Fryer, A. E., Harris, P. C. and Sampson, J. R. (1997) The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum. Mol. Genet. 6, 1991-1996
9. Jin, F., Wienecke, R., Xiao, G. H., Maize, Jr, J. C., DeClue, J. E. and Yeung, R. S. (1996) Suppression of tumourigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc. Natl. Acad. Sci. U.S.A. 93, 9154-9159
10. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J., Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley, D. and van der Sluijs, P. (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7, 1053-1057
11. Plank, T. L., Yeung, R. S. and Henske, E. P. (1998) Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res. 58, 4766-4770
12. Hodges, A. K., Li, S., Maynard, J., Parry, L., Braverman, R., Cheadle, J. P., DeClue, J. E. and Sampson, J. R. (2001) Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum. Mol. Genet. 10, 2899-2905
13. Gao, X. and Pan, D. (2001) TSC1 and TSC2 tumour suppressors antagonize insulin signaling in cell growth. Genes Dev. 15, 1383-1392
14. Potter, C. J., Huang, H. and Xu, T. (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105, 357-368
15. Matsumoto, S., Bandyopadhyay, A., Kwiatkowski, D. J., Maitra, U. and Matsumoto, T. (2002) Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe. Genetics 161, 1053-1063
16. Benvenuto, G., Li, S., Brown, S. J., Braverman, R., Vass, W. C., Cheadle, J. P., Halley, D. J., Sampson, J. R., Wienecke, R. and DeClue, J. E. (2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19, 6306-6316
17. Chong-Kopera, H., Inoki, K., Li, Y., Zhu, T., Garcia-Gonzalo, F. R., Rosa, J. L. and Guan, K. L. (2006) TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 281, 8313-8316
18. Nellist, M., Verhaaf, B., Goedbloed, M. A., Reuser, A. J., van den Ouweland, A. M. and Halley, D. J. (2001) TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum. Mol. Genet. 10, 2889-2898
19. Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E. and Hariharan, I. K. (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105, 345-355
20. Stocker, H. and Hafen, E. (2000) Genetic control of cell size. Curr. Opin. Genet. Dev. 10, 529-535
21. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. and Cantley, L. C. (2002) Identification of the tuberous sclerosis complex-2 tumour suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10, 151-162
22. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K. L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657
23. Potter, C. J., Pedraza, L. G. and Xu, T. (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4, 658-665
24. Montagne, J., Stewart, M. J., Stocker, H., Hafen, E., Kozma, S. C. and Thomas, G. (1999) Drosophila S6 kinase: a regulator of cell size. Science 285, 2126-2129
25. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B. and Pan, D. (2002) Tsc tumour suppressor proteins antagonize amino acid-TOR signalling. Nat. Cell Biol. 4, 699-704
26. Radimerski, T., Montagne, J., Hemmings-Mieszczak, M. and Thomas, G. (2002) Lethality of Drosophila lacking TSC tumour suppressor function rescued by reducing dS6K signaling. Genes Dev. 16, 2627-2632
27. Fingar, D. C. and Blenis, J. (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171
28. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945
29. Wullschleger, S., Loewith, R. and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
30. Guertin, D. A. and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
31. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468
32. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
33. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A. and Hall, M. N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128
34. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307, 1098-1101
35. Heitman, J., Movva, N. R. and Hall, M. N. (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909
36. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L. and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
37. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H. and Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U.S.A. 95, 1432-1437
38. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E. and Thomas, G. (1995) The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J. 14, 5279-5287
39. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R. and Sonenberg, N. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864
40. Mothe-Satney, I., Yang, D., Fadden, P., Haystead, T. A. and Lawrence, Jr, J. C., (2000) Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol. Cell. Biol. 20, 3558-3567
41. Fingar, D. C., Salama, S., Tsou, C., Harlow, E. and Blenis, J. (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/elF4E. Genes Dev. 16, 1472-1487
42. Goncharova, E. A., Goncharov, D. A., Eszterhas, A., Hunter, D. S., Glassberg, M. K., Yeung, R. S., Walker, C. L., Noonan, D., Kwiatkowski, D. J., Chou, M. M. et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumour suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277, 30958-30967
43. Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G. and Lamb, R. (2002) Tuberous sclerosis complex tumour suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159, 217-224
44. Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C. and Blenis, J. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U.S.A. 99, 13571-13576
45. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N. and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells. Hum. Mol. Genet. 11, 525-534
46. Kenerson, H. L., Aicher, L. D., True, L. D. and Yeung, R. S. (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumours. Cancer Res. 62, 5645-5650
47. Karbowniczek, M., Yu, J. and Henske, E. P. (2003) Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am. J. Pathol. 162, 491-500
48. El-Hashemite, N., Zhang, H., Henske, E. P. and Kwiatkowski, D. J. (2003) Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361, 1348-1349
49. Crino, P. B. (2004) Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J. Child Neurol. 19, 716-725
50. Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D., Kwiatkowski, D. J. and Cantley, L. C. (2005) Feedback inhibition of Akt signaling limits the growth of tumours lacking Tsc2. Genes Dev. 19, 1773-1778
51. El-Hashemite, N., Walker, V., Zhang, H. and Kwiatkowski, D. J. (2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63, 5173-5177
52. Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M. S., El-Hashemite, N. et al. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213-227
53. Messina, M. P., Rauktys, A., Lee, L. and Dabora, S. L. (2007) Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-γ, and comparison of rapamycin to CCI-779. BMC Pharmacol. 7, 14
54. Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G. and Crone, K. R. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490-498
55. Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., Salisbury, S. and Franz, D. N. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140-151
56. Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J. and Sampson, J. R. (2008) Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 358, 200-203
57. Patel, P. H., Thapar, N., Guo, L., Martinez, M., Maris, J., Gau, C. L., Lengyel, J. A. and Tamanoi, F. (2003) Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell Sci. 116, 3601-3610
58. Saucedo, L. J., Gao, X., Chiarelli, D. A., Li, L., Pan, D. and Edgar, B. A. (2003) Rheb promotes cell growth as a component of the insulin/TOR signaling network. Nat. Cell Biol. 5, 566-571
59. Stocker, H., Radimerski, T., Schindelholz, B., Wittwer, F., Belawat, P., Daram, P., Breuer, S., Thomas, G. and Hafen, E. (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5, 559-566
60. Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A. and Pan, D. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5, 578-581
61. Inoki, K., Li, Y., Xu, T. and Guan, K.-L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834
62. Tee, A. R., Manning, B. D., Roux, P. P., Cantely, L. C. and Blenis, J. (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268
63. Castro, A. F., Rebhun, J. F., Clark, G. J. and Quilliam, L. A. (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32493-32496
64. Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L. and Thomas, G. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457-1466
65. Im, E., vonLintig, F. C., Chen, J., Zhuang, S., Qui, W., Chowdhury, S., Worley, P. F., Boss, G. R. and Pilz, R. B. (2002) Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21, 6356-6365
66. Tabancay, Jr, A. P., Gau, C. L., Machado, I. M., Uhlmann, E. J., Gutmann, D. H., Guo, L. and Tamanoi, F. (2003) Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278, 39921-39930
67. Tee, A. R., Blenis, J. and Proud, C. G. (2005) Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett. 579, 4763-4768
68. Hsu, Y. C., Chern, J. J., Cai, Y., Liu, M. and Choi, K. W. (2007) Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445, 785-788
69. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A. and Sabatini, D. M. (2007) PRAS40 Is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915
70. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. and Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702-713
71. Urano, J., Comiso, M. J., Guo, L., Aspuria, P. J., Deniskin, R., Tabancay, Jr, A. P., Kato-Stankiewicz, J. and Tamanoi, F. (2005) Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol. Microbiol. 58, 1074-1086
72. Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y. and Jiang, Y. (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318, 977-980
73. Rosner, M., Hofer, K., Kubista, M. and Hengstschlager, M. (2003) Cell size regulation by the human TSC tumour suppressor proteins depends on PI3K and FKBP38. Oncogene 22, 4786-4798
74. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C. and Avruch, J. (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and elF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484-14494
75. Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J. and Proud, C. G. (2005) the tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280, 18717-18727
76. Long, X., Ortiz-Vega, S., Lin, Y. and Avruch, J. (2005) Rheb binding to mTOR is regulated by amino acid sufficiency. J. Biol. Chem. 280, 23433-23436
77. Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L. et al. (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 30H-kinase. Proc. Natl. Acad. Sci. U.S.A. 102, 14238-14243
78. Roccio, M., Bos, J. L. and Zwartkruis, F. J. (2006) Regulation of the small GTPase Rheb by amino acids. Oncogene 25, 657-664
79. Byfield, M. P., Murray, J. T. and Backer, J. M. (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076-33082
80. Findlay, G. M., Yan, L., Procter, J., Mieulet, V. and Lamb, R. F. (2007) A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem. J. 403, 13-20
81. Manning, B. D. and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274
82. Dan, H. C., Sun, M., Yang, L., Sui, R. M., Yeung, R. S., Halley, D. J. J., Nicosia, S. V., Pledger, W. J. and Cheng, J. Q. (2002) PI3K/Akt pathway regulates TSC tumour suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277, 35364-35370
83. Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J. and Gygi, S. P. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumour suppressors. Proc. Natl. Acad. Sci. U.S.A. 102, 667-672
84. Cai, S. L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., Guo, R., Johnson, C. L., Kiguchi, K. and Walker, C. L. (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 173, 279-289
85. Dong, J. and Pan, D. (2004) Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev. 18, 2479-2484
86. Plas, D. R. and Thompson, C. B. (2003) Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278, 12361-12366
87. Nellist, M., van Slegtenhorst, M. A., Goedbloed, M., van den Ouweland, A. M. W., Halley, D. J. J. and van der Sluijs, P. (1999) Characterization of the cytosolic tuberin-hamartin complex. J. Biol. Chem. 274, 35647-35652
88. Yamamoto, Y., Jones, K. A., Mak, B. C., Muehlenbachs, A. and Yeung, R. S. (2002) Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin. Arch. Biochem. Biophys. 404, 210-217
89. Deyoung, M. P., Horak, P., Sofer, A., Sgroi, D. and Ellisen, L. W. (2008) Hypoxia regulates TSC1/2 mTOR signaling and tumour suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239-251
90. Nellist, M., Goedbloed, M. A., de Winter, C., Verhaaf, B., Jankie, A., Reuser, A. J. J., van den Ouweland, A. M. W., van der Sluijs, P. and Halley, D. J. J. (2002) Identification and characterization of the interaction between tuberin and 14-3-3ζ. J. Biol. Chem. 277, 39417-39424
91. Shumway, S. D., Li, Y. and Xiong, Y. (2003) 14-3-3β binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumour suppressor gene product, tuberin. J. Biol. Chem. 278, 2089-2092
92. Tee, A. R., Anjum, R. and Blenis, J. (2003) Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J. Biol. Chem. 278, 37288-37296
93. Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P. and Blenis, J. (2004) Tumour-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumour suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U.S.A. 101, 13489-13494
94. Alessi, D. R., Caudwell, F. B., Andejelkovic, M., Hemmings, B. A. and Cohen, P. (1996) Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399, 333-338
95. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. and Pandolfi, P. P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193
96. Lee, D. F., Kuo, H. P., Chen, C. T., Hsu, J. M., Chou, C. K., Wei, Y., Sun, H. L., Li, L. Y., Ping, B., Huang, W. C. et al. (2007) IKKβ suppression of TSC1 links inflammation and tumour angiogenesis via the mTOR pathway. Cell 130, 440-455
97. Dennis, P. B., Jaeshke, A., Saitoh, M., Fowler, B., Kozma, S. C. and Thomas, G. (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294, 1102-1105
98. Inoki, K., Zhu, T. and Guan, K. L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590
99. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A. and Cantley, L. C. (2004) The LKB1 tumour suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99
100. Hardie, D. G. (2005) New roles for the LKB1→AMPK pathway. Curr. Opin. Cell Biol. 17, 167-173
101. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K. et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-968
102. Mak, B. C., Kenerson, H. L., Aicher, L. D., Barnes, E. A. and Yeung, R. S. (2005) Aberrant β-catenin signaling in tuberous sclerosis. Am. J. Pathol. 167, 107-116
103. Arsham, A. M., Howell, J. J. and Simon, M. C. (2003) A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278, 29655-29660
104. Liu, L., Cash, T. P., Jones, R. G., Keith, B., Thompson, C. B. and Simon, M. C. (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521-531
105. Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W. and Kaelin, Jr, W. G. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumour suppressor complex. Genes Dev. 18, 2893-2904
106. Reiling, J. H. and Hafen, E. (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18, 2879-2892
107. Sofer, A., Lei, K., Johannessen, C. M. and Ellisen, L. W. (2005) Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell. Biol. 25, 5834-5845
108. Astrinidis, A., Senapedis, W., Coleman, T. R. and Henske, E. P. (2003) Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem. 278, 51372-51379
109. Zacharek, S. J., Xiong, Y. and Shumway, S. D. (2005) Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 65, 11354-11360
110. Li, Y., Inoki, K., Vacratsis, P. and Guan, K. L. (2003) The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 278, 13663-13671
111. Manning, B. D. (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumourigenesis. J. Cell Biol. 167, 399-403
112. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R. et al. (2004) The TSC1-2 tumour suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223
113. Shah, O. J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival defects. Curr. Biol. 14, 1650-1656
114. Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D. and Kwiatkowski, D. J. (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117, 730-738
115. Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L. and Kwiatkowski, D. J. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223-1233
116. Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M. and Manning, B. D. (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24, 185-197
117. Huang, J., Dibble, C. C., Matsuzaki, M. and Manning, B. D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol., doi:10.1128/MCB.00289-08
118. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H. and Sawyers, C. L. (2001) Enhanced sensitivity of PTEN-deficient tumours to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U.S.A. 98, 10314-10319
119. +/- mice. Proc. Natl. Acad. Sci. U.S.A. 98, 10320-10325
120. Dasgupta, B., Yi, Y., Chen, D. Y., Weber, J. D. and Gutmann, D. H. (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumours. Cancer Res. 65, 2755-2760
121. Johannessen, C. M., Johnson, B. W., Williams, S. M., Chan, A. W., Reczek, E. E., Lynch, R. C., Rioth, M. J., McClatchey, A., Ryeom, S. and Cichowski, K. (2008) TORC1 is essential for NF1-associated malignancies. Curr. Biol. 18, 56-62
122. Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E. and Cichowski, K. (2005) The NF1 tumour suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U.S.A. 102, 8573-8578
123. Wei, C., Amos, C. I., Zhang, N., Wang, X., Rashid, A., Walker, C. L., Behringer, R. R. and Frazier, M. L. (2008) Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin. Cancer Res. 14, 1167-1171
124. Abel, T. W., Baker, S. J., Fraser, M. M., Tihan, T., Nelson, J. S., Yachnis, A. T., Bouffard, J. P., Mena, H., Burger, P. C. and Eberhart, C. G. (2005) Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J. Neuropathol. Exp. Neurol. 64, 341-349
125. Aoki, M., Blazek, E. and Vogt, P. K. (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. U.S.A. 98, 136-141
126. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R. et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601
127. Skeen, J. E., Bhaskar, P. T., Chen, C. C., Chen, W. S., Peng, X. D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H. and Hay, N. (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10, 269-280
128. Riemenschneider, M. J., Betensky, R. A., Pasedag, S. M. and Louis, D. N. (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 66, 5618-5623
129. Ma, L., Teruya-Feldstein, J., Bonner, P., Bernardi, R., Franz, D. N., Witte, D., Cordon-Cardo, C. and Pandolfi, P. P. (2007) Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 67, 7106-7112
130. Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J. and Thomas, G. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205